Here’s What Happened at PropThink This Week

  • Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King first wrote on the name in December has returned more than 60%, but we believe it’s time to take profits.
  • PropThink subscribers knew to short Novogen (NVGN) in late February after the stock popped well above fair value. That trade has pulled in 66% in less than a month.


  • BMRN is up 21% since we last wrote on the name. Ivan Deryugin outlined why he still likes the stock and believes there’s upside from here.
  • Sarepta just keeps working higher. PropThink considers this a great long-term holding, and we outlined our strategy for being involved over the near-term. Shares are already up 18% in the last month.
  • As expected, THLD proved a quality derivative play on ZIOP’s Phase III Palifosfamide data. The trade pulled in a quick 10% when the stock popped a few days after Mr. Patel’s story